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Mutagenesis after Cancer Therapy
by Karl T. Kelsey,1 Michele Caggana,2 Peter M. Mauch,3
C. Norman Coleman,4 John R. Clark,5 and Howard L.
Liber'
A subset of Hodgkin's disease (HD) and breast cancer patients have been reported to have elevated hprt
mutant frequencies in peripheral blood lymphocytes after cessation oftherapy. A subset ofthese patients are
also known to develop second therapy-related malignancies. Therefore, it is clearly important to determine if
theseelevations in mutantfrequencyrepresenttrue,persistentlyelevatedmutationfrequencies.As afollow-up
to our study ofpatients previously treated for HD, we recruited for a prospective study six previously treated
HD patients and five patients who had been treated for squamous cell carcinoma ofthe head and neck. These
individuals were studied several times over a 6-7 months. The results confirmed that a subset ofpatients have
persistently highmutantfrequencieswhencomparedto71previouslystudiedcontrols.Thestudywasdesigned
to determine if the elevated mutant frequencies of treated patients represented independent mutations or
resulted from thein vivo expansion ofsingle mutant cells. We usedthe polymerase chain reaction to examine
DNAsinglestrandconformation polymorphismsattheT-cellreceptor-y locusofindividual mutantclones.This
analysis showed that 20.1% of the mutants from Hodgkin's disease patients and 17.5% of the mutants from
squamous cell carcinoma patients were siblings. The sibling mutants generally did not persist over time.
However, one patient had one mutant clone that persisted, but slowly decreased in prevalence over a 7 month
sampling period. The data demonstrate that treatments for cancer result in persistently elevated mutation
frequencies at the hprt locus in some, but not all, patients. In addition, our results confirm previous studies
indicating that it is not always appropriate to assume equality between mutant and mutation frequencies
when studying individuals exposed to significant doses ofknown mutagens or carcinogens.
Introduction
Hodgkin's disease (HD) is among the most curable of
cancers in that approximately 90% ofpatients with early-
stage disease and 68% ofpatients with late stage disease
are cured, as defined by remission of 5 years or more.
Unfortunately, studies by a number ofinvestigators have
shown that patients in successful remission have a higher
than expected riskforsecondary cancers, includingleuke-
miaand solid tumors (1-9). The emergence ofsolid tumors,
'Department of Cancer Biology, Laboratory of Radiobiology and
Occupational Health Program, Harvard School ofPublic Health, Boston,
MA 02115.
2Wadsworth Center for Laboratories and Research, New York State
Department of Health, Albany, NY.
'Joint Centerfor Radiation Therapy, Harvard Medical School, Boston,
MA 02115.
'Department of Radiation Therapy, Joint Center for Radiation Ther-
apy, Harvard Medical School, Boston, MA 02115.
5Dana Farber Cancer Institute, Boston, MA 02115.
6Department ofCancerBiology, Laboratory ofRadiobiology, Harvard
School of Public Health, Boston, MA 02115.
Address reprint requests to K. T. Kelsey, Laboratory ofRadiobiology,
Harvard School of Public Health, 665 Huntington Avenue, Boston, MA
02115.
including those ofthe lung and breast, occurs as the time
after successful radiotherapy or chemotherapy for HD
increases beyond 10 years (1,8). The second cancer risk
correlates with the type oftreatmentthepatientreceived,
with those experiencing the most intensive treatment at
highest risk. Relative risk estimates up to 117 have been
reported (8) for the development of leukemias in some
long-term survivors who were treated with combination
therapy of X-rays and chemotherapy. In those receiving
radiation alone, a relative risk of11 for leukemia has been
reported in long-term survivors (8). At 15 years offollow-
up, the solid tumor risk continues to increase; however,
this risk has not been associated with a particular treat-
ment type.
It has become clear that many neoplasms arise as the
result of mutational events. Some cancers are heritable,
including retinoblastoma (9,10), Wilms' tumor (11,12), and
familialpolyposis/colon cancer(13). Interestingly,thegene
that is lost during the formation ofretinoblastoma is also
associated with the development of osteosarcomas (14),
breast(15,16) andbladdercancer(17), andsmallcarcinoma
of the lung (18). These findings suggest that a genetic
alteration, inherited at birth or occurring in somatic cells
during life, increases the chance of developing cancer.KELSEY ET AL.
Therefore, administration of a mutagenic treatment for a
primary cancer mayfurtherincreasethe chances ofdevel-
opment ofsecond cancer byinducing heritable alterations
of tumor-associated genes, such as seen with osteosar-
coma after radiation treatment for retinoblastoma.
One ofthemostconvincing studies associatingcytotoxic
therapy with secondary leukemia has been reported by
LeBeau et al. (19). They showed that 17/63 patients with
therapy-related acute nonlymphocytic leukemia and
myelodysplastic syndrome had interstitial deletions onthe
long arm (q) ofchromosome 5. Furthermore, the deletion
encompassed the chromosome region 5q23-5q32. This
region is known to include a number of hematopoietic
growth factors, which may play a role in leukemia forma-
tion. Similar consistent alterations have been demon-
strated on chromosome 7.
Laboratory techniques to detect the emergence of cell
clones that carry specific changes associated with second
cancers are continuouslybeingdeveloped. The goal ofthis
research is to make these techniques applicable in a
routine clinical setting; this can occur once the methods
are validated, cost effective, and widely available. Most of
the assays have not yet evolved to this stage.
Because only a subpopulation ofthepatients receiving a
giventherapyforHD develops asecond cancer, wefeltthat
it was importantto determinewhethercertain individuals
are hypersensitive to the induction of secondary genetic
effects by the treatment for their HD and whether or not
such differential sensitivitytotherapy maybeindicative of
risk for second cancers. To investigate this, we have used
an assay developed by several investigators (20-28) to
measure mutations induced in peripheral blood lympho-
cytes. Mutation at the hypoxanthine-guanine phosphori-
bosyl-transferase (hprt) locus, an enzyme that serves as a
salvage pathwayfornucleotide biosynthesis, is assayed by
growth ofthe cells in a selective media containing 6-thio-
guanine. In the presence of this guanine analog, cells
deficient in HPRT can survive. If cells from a treated
individual are sampled and grown in 6-thioguanine, the
frequency of mutants can be determined; this mutant
frequency is an indication of overall somatic mutation
induced by therapy.
Somatic Mutation in Controls
Table 1 summarizes data obtained from controls. The
mean mutant frequency (MF) in current smokers was 5.6
X 10-6. In ex-smokers the mean MF was3.8 x 10-6 , and
in never-smokers it was 4.4 x 10-6. The mean MF in the
whole control group was 4.6 x 10-6. The MFs ranges
from 0.5 to 27.7 x 10-6, with an upper 95% confidence
limitof12.6 x 10-6.Currentsmokershad a meanMFthat
was 1.3-fold greater than nonsmokers (combined ex-
smokers and never-smokers).
The effects of smoking, age, and gender on MF were
examined using ANOVA. Current smoking was modeled
using a"dose" term,which wasweightedbythe numberof
pack-years smoked; that is, smoking = (age at venipunc-
ture - age smoking started) x number ofpacks smoked
perday.Whensmokingstatus wasincludedinthemodelin
terms of pack-years, age did not significantly affect MF
(slope = 0.035, R = 0.139). However, gender (p = 0.039)
and smoking (p = 0.007) significantly affected MF. In
nonsmokers (never-smokers and ex-smokers) alone, age
had a borderline significant effect on MF (p = 0.059),
whereas gender was not significantly associatedwith MF.
In current smokers alone, neither age nor gender signifi-
cantly affected MF.
TheMFs ofthree controls wererepeatedly studied over
a 1.5-year period. These data are shown in Table 2. The
within individual variation in MF (Table 2) was less than
the between individual variation among controls (Table 1).
The variance ofcontrol 1 and control 3 were significantly
different when compared to the variance of the whole
control group (p < 0.05, F-test).
Therefore, our datafrom control MFs were generally in
the range of 0.5-10.0 x 10-6. Smoking was associated
with an elevation in MF when apack-year term quantitat-
Table 1. Cloning efficiency (CE) and mutant frequency (MF) in smoking and nonsmoking controls.
Age CE MF x 10-6
Group Mean + SD Range Mean ± SD Range Mean ± SD Range
Current smokers (n = 18) 40.9 ± 15.2 18-65 28.8 ± 19.9 5.0-68.2 5.6 ± 6.4 1.5-27.7
Ex-smokers (n = 30) 54.8 + 14.2 23-80 23.2 + 20.0 2.7-94.1 3.8 ± 3.2 0.5-16.5
Never-smokers (n = 23) 39.4 ± 16.7 18-73 13.2 + 10.8 1.3-37.0 4.4 ± 3.2 0.7-15.4
Nonsmokers (never-smokers and ex-
smokers) (n = 53) 48.2 + 17.0 18-80 18.9 ± 17.2 1.3-94.1 4.1 ± 3.2 0.6-16.5
All controls (n = 71) 46.3 + 16.7 18-80 21.1 ± 18.2 1.3-94.1 4.6 + 4.3 0.5-27.7
aMean cloningefficiency is the average ofduplicate plates seeded at 2, 5, and 10 cells per well.
TIble 2. Cloning efficiency (CE) and mutant frequency (MF) in controls repeated over 1.5 years.
CE, % MF x 10-6
Subject na Mean ± SDb Range Mean ± SD Range
Control 1 26 31.0 + 23.2 1.4-104.0 3.4 ± 2.8 0.5-9.3
Control 2 9 17.4 ± 9.1 7.3- 36.1 5.5 ± 2.9 1.1-9.2
Control 3 7 41.7 ± 15.2 13.6- 62.8 2.4 ± 1.3 0.5-3.9
aNumber ofindividual experiments.
bMean cloning efficiency is the average ofduplicate plates seeded at 2, 5, and 10 cells per well.
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ing cigarette "dose" was used in a model testing factors
affecting MF in the controls. Smoking also was shown to
have asignificant effect on MF in a studyreportedbyCole
et al. (23). In a study that included a small number of
smokers (n = 4), Henderson et al. (25) reported a nonsig-
nificant increase in MF associated with smoking. Among
all controls, we found gender to significantly affect MF. In
nonsmokers alone, however, the effect of age on MF
approached significance, and gender had no effect. In
smokers, neither age norgender affected MF.Vijayalaxini
and Evans (29) and Cole et al. (23) reported no significant
effect of gender on MF; however, they found a small
increase in MF associated with age. Henderson et al. (25)
also reported a small nonsignificant effect of age on MF.
Trainor et al. (30) have also reported increase in age to be
associated with increase in MF athprt. Large numbers of
study subjects at the extremes of age maybe required for
theeffectofage onMF tobecomedetectable. Forinstance,
when newborn cord blood samples were included in the
model testing for age effects, age significantly affected
MF in the study by Henderson et al. (25).
Data from these controls, studied throughout a 1.5-year
period, indicate that the MF remains stable over time in
healthy controls. In addition, the variance within multiple
samples on the same subject is less than samples between
different individuals. These data are consistent with the
findings ofothers (24,25,28). The mean control MF, 4.6 x
10-6,is also similartothatpreviouslyreported (20-26,28).
Untreated HD Patients
Eighteen individuals with HD were studied before
receiving any treatment (Table 3). The mean age of this
cohort was29.6 + 10.3 years. Theuntreatedpatients had a
significantly lower cloning efficiency (CE) than controls
(11.3% versus 21.1%; p = 0.015,Wilcoxon test) and ahigher
MF (7.6 x 10-6 versus 4.6 x 10-6). The MF ofthe new
patients did not differ significantly from the controls.
ANOVAshowed that age, smoking, stage atdiagnosis, and
gender did not affect MF in this patient group.
The subjects in the untreated HD cohort (newpatients)
hadlowerCEswhencompared tocontrols.There are some
reports of decreased responsiveness of lymphocytes to
mitogenic stimulation in vitro from HD patients (31-35),
which may explain the consistently lower CEs obtained in
our study. Asimilar decrease in CE in cancerpatients has
been observed in an untreated breast cancer cohort (36).
The MF in the untreated HD cohort (new patients) was
not different from that in the control group. However, the
presenceof3of18 personswith anelevatedMF (above12.6
x 10-6) suggests that a fraction of HD patients begin
therapy with MFs higher than the control level.
Radiation Therapy Treatment of HD
Patients
Forty-five patients received onlyradiotherapy (Table 3).
These patients had completed therapy 2-183 months
before sampling. Their mean age was 35.1 + 12.8 years.
The mean CE for this group was 10.1% + 7.6%, and the
mean MF was 15.6 + 24.4 x 10-6 (Table 3). The CE was
significantly different from the controls (p = 0.002,
Wilcoxon).
The MFs in the radiotherapy and control groups dif-
fered significantly (p = 0.0001,Wilcoxon). In the radiation
cohort, the majority ofpatients (69%) had MFs below the
95% confidencelevelforMF ofcontrols,while31% ofthese
patients had MFs above this value (14 of45).
There was no significant correlation (R = -0.141)
between MF and time after completion oftreatment. The
effects ofstage at diagnosis, age, gender, and smoking on
MF were analyzed using ANOVA. When the model
included the staging classification "A" or "B" (which indi-
cates the absence or presence of systemic symptoms -
fevers, night sweats, weight loss, etc.), age (p = 0.03) and
stage (p = 0.03) were associated with MF. Gender and
smoking had no effect on MF. However, when the stage
classification was based only on nodal involvement (i.e.,
IIAand IIB areclassified together), age,gender, smoking,
and stage were no longer associated with MF.
HD Patients Treated with
Chemotherapy
Among all patients studied, two received only chem-
otherapy. One (CHT1) was 40 years old, had a CE of1.1%,
an estimated maximal MF of 8.0 x 10-6 (no mutants
observed/576 wells plated), and had completed therapy 30
monthsbeforethisstudy.Theotherpatient(CHT2) was39
years old, had aCE of5.1%, and anelevated MF of183.9 x
10-6 (66 mutant clones/383 wells plated). CHT2 had com-
pleted chemotherapy several days before the study.
Twenty-three ofthe patients studied were treated with
both radiation and chemotherapy (Table 3). The mean age
forthis group was 34.3 + 14.1 years. They were studied 9-
174 months after their last treatment, except for one
patient who was currently undergoing radiotherapy but
hadfinished chemotherapy. The mean CE,10.7% ± 13.6%,
Table 3. Cloning efficiency (CE) and mutant frequency (MF) in Hodgkin's patients and controls.
Age CE MF x 10-6
Group Mean + SD Range Mean ± SDa Range Mean ± SD Range
Controls (n = 71) 46.3 ± 16.7 18-80 21.1 ± 18.2 1.3-94.1 4.6 ± 4.3c 0.5- 27.7
New patients (n = 18) 29.6 ± 10.3 16-54 11.3 ± 10.0 1.5-34.3 7.6 + 9.4 0.9- 41.0
Radiation (n = 45) 35.1 ± 12.8 18-75 10.1 ± 7.6 1.1-36.2 15.6* ± 24.4 0.6-128.9
Combination (n = 23) 34.3 ± 14.1 19-84 10.7 ± 13.6 1.1-65.0 15.7* ± 12.4 1.4- 40.9
aMean cloning efficiency is the average ofduplicate plates seeded at 2, 5, and 10 cells per well.
*Significantly different from the control MF (p < 0.001; see text).
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was statistically different from controls (p = 0.007,
Wilcoxon); the MF, 15.7 + 12.4 x 10-6, was significantly
elevated over the control mean (p = 0.0001, Wilcoxon).
ANOVA showed that there was no significant association
between MF and age, stage at diagnosis, or smoking
history.
Of the 23 patients receiving combined chemotherapy
and radiotherapy, 44% (10 of22) had MFs exceeding the
upper 95% confidence level for controls. Thus, a greater
proportion ofthese patients had elevated MFs than those
receiving radiation therapy only (31%). Asubpopulation of
patientMFswerewithincontrolvaluesof0.5-10.0 x 10-6.
There alsowas no significant downward trend in MFwith
time after therapy in these treated patients (R = 0.288).
A study by Ammenheuser et al. (37) using an auto-
radiographic assay has shown that the MF transiently
increases during and immediately afterpatienttreatment
with cyclophosphamide. However, the MF decreases to
near baseline levels shortly after cessation of treatment
(1-2months), suggestingselection againsthprtmutantsor
cell turnover and repopulation. Recent studies by Nicklas
et al. (38) on patients who were currently receiving radi-
oimmunotherapy also reported elevated MFs, which were
shown tobe due to independent mutations byT-cell recep-
tor studies. In neither of these studies, however, were
patients studied years after cessation oftreatment. Stud-
iesbySala-Trepatetal. (39) showelevated MFsinpatients
who were sampled at various times (months) after treat-
ment with radiation and chemotherapy for breast cancer.
It is possible that in a subset of patients, independent
mutations will persist in long-lived lymphocytes. The
extent of persistence may be related to the exposure
(radiation and/or chemotherapy) or to an inherent sen-
sitivity ofsome lymphocytes to the exposure. It is clearly
important to investigate the nature of the elevated MFs
that are evident years after therapy ends.
respond directly to such therapies. Furthermore, com-
bined modality therapy is more intensive than radi-
otherapy. During radiotherapy, some lymphocytes are
likely to escape exposure entirely. However, in combined
modality therapy, these cells are exposed to systemic
chemotherapy, which affects all lymphocytes, some of
which may already have been damaged by radiation.
An elevated MF may result from two causes. It may
arise after expansion of a particular mutant clone, or it
may be due to an increase in the number ofindependent
mutants. In the first case, elevation ofMF maybe caused
by antigenic stimulation ofapreexisting hprt mutant or a
cell carrying pre-mutagenic damage in the hprt gene. In
treated patients, long-lived Go lymphocytes with such an
altered hprt gene mayundergo blastogenesis as part ofa
normal immune response, resulting in a quantifiable
increase in MF. The MF might then decrease after the
immunological response is complete.
This type of expansion of a mutant clone has been
previously observed in an otherwise healthy nurse (40).
Similarly, a study on atomic bomb survivors showed that
when the clonal mutants are enumerated and the number
ofactualindependentmutationaleventsdetermined, those
withelevated MFs hadnormalmutationfrequencieswhen
compared to controls (41). Thus, it is possible that all
patients have a similarlevel ofmutagenic damage induced
in the hprt gene, but that the damage is visible as hprt
mutants in only a subset, based on the probability of a
particularT-cellrespondingto anantigenic stimulus later.
Alternatively, there maybe inherentvariation amongpeo-
pleinsusceptibilitytoradiationorchemical-inducedmuta-
tions. If that were true, then new mutations would be
induced in only a subset of patients. These possibilities
could be distinguished by T-cell receptor studies. If the
first alternative were correct, then most ofthe observed
mutants would have the same T-cell receptor pattern. If
the second were correct, then most ofthe mutants would
have different patterns.
Possible Explanations for Persistently
Elevated Mutant Frequencies in HD Prospective Study to Determine the
Patients Incidence of Sibling Mutants in
Treated HD Patients
Some radiotherapy patients have elevated MFs when
compared to the controls; two distinct subpopulations are
evident. One of these had MFs that were comparable to
controls, irrespective of treatment. The fraction of
patients with elevated MFs in the radiation-only cohort
(31%) ishigherthanthatobservedinthe untreated cohort
(17%). Thus, itisunlikelythatthoseradiotherapypatients
with high MFs after therapy all began treatment with
previously elevated MFs. In fact, after radiotherapy, the
elevated fraction hadjust about doubled.
The emergence ofa subpopulation with elevated MFs is
even more strikingwhen the MFs ofthose receivingboth
chemotherapy and radiotherapywere examined. Ahigher
fraction ofthis cohorthadelevated MFs (44%). Thevaria-
tioninMFinboth ofthesegroups (radiation andcombina-
tion)wasgreaterthanthevariationinthecontrols,further
suggesting that the lymphocytes from different patients
We conducted aprospective study to further character-
ize the prevalence of independent and sibling (clonal)
mutantlymphocytesintreatedcancerpatients.Weapplied
atechnique usingthepolymerase chain reaction (amplify-
ing a variable region within the T-cell receptor-y gene
locus) combined with DNA single strand conformation
polymorphism gel electrophoresis (PCR/SSCP) to deter-
mine the proportions of unique and sibling mutants that
appeared in the cloning wells (42,43). We used this PCR/
SSCPtechnique to examineprospectively sets ofmutants
isolated from patients treated for HD and squamous cell
carcinoma (SCC) of the head and neck after repeated
samplings.
Six HD patients (patients A-F) and five SCC patients
(patients G-K) who had completed therapy were studied
prospectively over 6-7 months (Table 4). The majority of
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Table 4. Demographic data from treated cancer patients enrolled
in the prospective study.
Subject Current smoker
ID Diagnosis Age Treatment (pack-years)c
A HD 36 IRR, MOPP NO
B HD 24 IRR, MOPP YES (1.5)
C HD 39 IRR, MOPP NO
D HD 30 IRR, MOPP YES (7)
E HD 29 IRR NO
F HD 48 IRR YES (23)
G SCC 61 IRR, PFL YES (60)
H SCC 37 IRR, PFL NO
I SCC 60 IRR, PFL YES (40)
J SCC 66 IRR, PFL NO
K SCC 51 IRR NO
Abbreviations: HD, Hodgkin's disease; SCC, squamouscellcarcinoma;
MOPP, mechlorethamine, oncovin, prednisone, procarbazine; PFL,
cisplatin, 5-fluorouracil, leucovorin; IRR, radiotherapy.
cCigarette smoking history in pack years: years smoked x packs
smoked per day.
these patients studied were treated with a combination of
chemotherapy and radiotherapy.
Each patient was sampled three to six different times.
AfterdeterminingthehprtMF,allmutantclonesand5-10
nonselectedclones(grownintheabsenceof6-thioguanine)
were removed from the microtiter wells and subjected to
PCR/SSCP analysis. These data were analyzed for the
incidence of sibling mutants by examining the banding
patterns on the autoradiograms (Tlbles 5 and 6). Several
patients were noted to have sibling clones.
Mutation frequencies foreach samplingwere calculated
bycountingeachindependentmutantand siblinggroupas
onemutation. Inmostcases,the MF closelyapproximated
the mutation frequency (Tables 5 and 6). There were no
significanttrends in MF ormutationfrequency overtime,
with the exception ofpatient F (Tlable 5). This patient had
one sibling clone that was found in each peripheral blood
Table 5. Mutant frequency (MF), incidence ofsibling mutants (Sibs), and mutation frequency in a prospective study of
Hodgkin's disease patients.
Subject ID'
A-1
A-2
A-3
A-4
B-1
B-2
B-3
B-4
C-i
C-2
C-3
C-4
D-1
D-2
D-3
D-4
Eld
E-2
E-3
Fld
F-2
F-3
F-4
F-5
Months
since last
treatment
30
32
34
37
28
29
34
36
31
32
36
38
34
35
37
40
41
43
48
35
36
37
39
42
% CE
13.9
7.0
3.7
15.1
12.6
21.7
26.6
11.2
15.6
10.6
9.9
13.2
5.9
11.5
11.6
34.3
55.0
21.0
20.4
16.3
7.3
12.9
5.2
5.1
No. of
positive wells
5
6
4
25
10
17
31
27
85
43
60
44
8
38
10
35
11
65
20
35
36
21
6
12
No. of wells
plated
960
768
948
768
768
384
768
576
960
768
960
960
576
576
768
384
960
960
768
576
960
576
480
768
MF x 10-6
1.9
5.6
5.7
11.0
5.2
10.6
7.5
21.4
29.7
28.8
32.6
17.8
11.8
29.7
5.6
13.9
1.1
16.7
6.5
19.2
26.2
14.4
12.1
15.4
SIBSb
0
0
0
1:C
0
0
1:7
1:2
3:2
2:3
2:3
2:2
1:3
1:5
1:4
0
1:4
1:2
0
1:2
1:3
1:3
1:2
1:5
1:9
1:2
1:3
1:3
1:19
1:17
1:4
1:2
1:le
No. of
independent
mutations
5
6
4
19
10
17
25
26
78
39
52
41
8
33
10
32
8
50
18
17
18
13
5
12
Mutation
frequency x
10 -6
1.9
5.6
5.7
8.3
5.2
10.4
6.2
26.6
27.2
24.6
28.1
16.5
11.8
25.7
15.6
12.7
0.8
12.7
5.8
9.2
14.4
12.3
10.1
15.4
aBolded IDs indicate combination therapy patients.
bClonally derived mutants = no. ofdifferent sibling groups (banding patterns): no. ofclones in group. cSeven clones with one identical banding pattern.
dPatients E and F were radiotherapy patients.
eSibling identical to others from patient F was identified.
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Table 6. Mutant frequency (MF), incidence ofsibling mutants (Sibs), and mutation frequency
in a prospective study ofsquamous cell carcinoma patients.
Subject ID'
G-1
G-2
G-3
G-4
G-5
H-1
H-2
H-3
H-4
H-5
I-1
I-2
I-3
'-4
I-5
1-6
J-1
J-2
J-3
J-4
Kld
K-2
K-3
Months
since last
treatment
9
10
11
13
14
4
5
6
8
10
6
7
8
9
10
11
4
5
8
9
3
4
8
% CE
7.1
2.7
4.8
3.7
6.9
21.0
19.7
27.4
18.7
25.1
10.8
11.1
14.3
8.8
12.4
17.1
34.6
9.1
17.2
15.1
1.8
34.0
26.8
No. of
positive wells
4
4
14
8
7
11
8
9
18
29
3
2
2
14
13
10
22
6
9
14
1
8
12
No. ofwells
plated
192
288
384
192
384
192
476
192
288
384
384
384
288
768
576
192
384
384
288
384
480
384
288
MF x 10-6
14.8
25.9
38.7
57.5
13.3
14.0
4.3
8.8
17.3
15.6
3.6
2.4
2.4
10.5
9.2
15.6
8.5
8.7
9.2
12.3
5.8
3.1
7.9
aBolded IDs are combination therapy patients.
bClonally derived mutants = no. ofdifferent sibling groups (banding patterns): no. ofclones in group.
CrTwo clones with one identical banding pattern.
dPatient K is radiotherapy patient.
Table 7. Mean mutation frequency in treated cancer patients
compared to 71 healthy historical controls.
Mean mutation
frequency
Group Patient na (x 10-6) + SD
Hodgkin's disease A 4 5.4 + 2.6
B 4 10.6 7.0
C 4 24.1 ±5.3
D 4 16.5 6.4
E 3 6.4 6.0
F 5 12.3 ± 2.7*
Squamous cell G 5 27.1± 13.5b
carcinoma H 5 11.0 ± 4.5*
I 6 6.6 5.1
J 4 9.4 2.1*
K 3 5.6 2.4
Historical (71 healthy 4.6 4.3c
controls (14) individuals)
Upper 95% 12.6
confidence
limit for MF in
controls
aNumber ofindependent determinations ofmutation frequency.
bAbove 95% confidence interval from historical controls.
cHistorical data is mutant frequency.
*Significantly different from controls (p < 0.05, Student's t-test).
sample and persisted for 7 months. The prevalence ofthis
clone declined with each time point (54.3%, 47.2%, 19.1%,
33.3%, 8.3% oftotal mutant clones observed). When these
clones wereremovedfromtheanalysis andcounted asonly
one mutation, the patient's mutation frequency was gener-
ally within the normal range, even though the MF
appeared elevated. When each individual's mutation fre-
quency was estimated as the mean ofthe repeat measure-
ments, and compared to the historical mean for healthy
controls, itwasclearthatseveralpatientshadsignificantly
elevated mutation frequencies, while others were within
the normal range (Table 7). Thus, this prospective study
confirmed ourearlierobservationthatthereis apersistent
elevation in hprt mutation frequencyin a subset oftreated
cancer patients (44).
Conclusions
Wehaveshownthat asubsetofpatientstreated success-
fully for HD with either radiotherapy alone or combined
modality (radiotherapy and chemotherapy) months to
yearsbeforethestudyhave MFsthat arewithinthe range
ofcontrols. However, otherpatients treated similarly have
elevated MFs (44). This finding is consistent with recent
SIBSb
0
0
0.
1:2c
1:2
0
0
0
0
1:5
1:2
0
0
0
0
1:3
1:3
1:2
1:2
0
1:3
1:2
0
0
0
0
0
0
No. of
independent
mutations
4
4
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work of Branda et al. (45). Therefore, we initiated this
prospective study to determine if those patients with
elevated MFs have an increased prevalence of sibling
mutants or a higher frequency ofindependent mutations.
The results generally were consistent with the latter
explanation. For both groups of treated cancer patients,
the MF was approximately equal to the mutation Fre-
quency. The contribution to MF from sibling mutants did
not appear to alter the analysis when examined overall,
and some patients had persistently elevated mutation fre-
quenciesyears aftercessation oftherapy. Thus,thealtera-
tions in MFwhichwe observed inthetreated HD patients
mayindicate atypeofpersistentgenetic damageresulting
fromtreatment. Thisis consistentwiththeworkofO'Neill
et al. (28) and Nicklas et al. (46). These investigators
detected smallnumbers ofsiblingclonesincontrolpopula-
tions (approximately 10% oftotal mutants collected)when
they used Southern blotting to analyze rearrangements
occurring at the T-cell receptor-,B gene locus; in these
experiments, the MF was also a good estimator of the
mutation frequency.
The MFs in these treated HD and small-cell carcinoma
patients were generally stable over the multiple sampling
times.Thepatientstended tohaveeitherconsistentlyhigh
(>12 x 10-6) orconsistently low(within the normal range
of1-12 x 10-6) MFs, although some variation did occur.
One HD patientunderwent a significant clonal expansion,
which greatly affected the MF. This also has been
observed previously in two other studies (40,41). There-
fore, we believe it is likely that the treatments induced
persistentlyelevatedmutationfrequencies inonlyasubset
ofpatients.
Previous work in primates suggests that in vivo expo-
sure to DNA alkylating agents can induce persistent
genetic damage, detectable long after initial exposure.
Zimmer et al. (47) recently reported that a single intra-
peritonealinjection ofethylnitrosourea (ENU)induced an
elevated hprt mutant frequency in peripheral blood lym-
phocytes oftwo cynomolgus monkeys thatpersisted for at
least 2 years. Kelsey et al. (48,49) also reported that
ethylene oxide induces sister chromatid exchanges in the
lymphocytes of cynomolgus monkeys that are detectable
6-7 years after cessation of chronic inhalation exposure.
These observations are consistent with our current dem-
onstration that cancer therapy induces persistent genetic
damage, detectable as elevated hprt mutation frequencies
in a subset oftreated patients.
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